Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All azvudine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAzvudineAzvudine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Progression 24% Improvement Relative Risk Azvudine for COVID-19  Liu et al.  LATE TREATMENT Is late treatment with azvudine beneficial for COVID-19? Retrospective 572 patients in China (December 2022 - January 2023) Lower progression with azvudine (not stat. sig., p=0.44) c19early.org Liu et al., Heliyon, October 2023 Favors azvudine Favors control

Clinical characteristics, outcomes, and risk factors of SARS-CoV-2 breakthrough infections among 572 fully vaccinated (BBIBP-CorV) hospitalized patients

Oct 2023  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Azvudine for COVID-19
41st treatment shown to reduce risk in July 2023
 
*, now known with p = 0.00014 from 18 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19early.org
Retrospective 572 fully vaccinated hospitalized patients in China, showing lower risk with azvudine treatment, without statistical significance. The composite outcome included intubation, non-invasive respiratory support, ICU admission, and all-cause death. Azvudine was not included in the multivariable analysis (only combined antiviral therapy was used without explanation).
Study covers azvudine and paxlovid.
risk of progression, 24.1% lower, RR 0.76, p = 0.44, treatment 12 of 126 (9.5%), control 56 of 446 (12.6%), NNT 33, intubation, non-invasive respiratory support, ICU admission, and all-cause death.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Liu et al., 21 Oct 2023, retrospective, China, peer-reviewed, 4 authors, study period 5 December, 2022 - 31 January, 2023. Contact: 962881298@qq.com, dengguangtong@outlook.com.
This PaperAzvudineAll
Clinical characteristics, outcomes, and risk factors of SARS-CoV-2 breakthrough infections among 572 fully vaccinated (BBIBP-CorV) hospitalized patients
Yihuang Liu, Peilin Liu, Yuming Sun, Guangtong Deng
Heliyon, doi:10.1016/j.heliyon.2023.e21387
Background: Breakthrough infections have been widely reported in vaccinated individuals. However, the clinical characteristics, outcomes, and risk factors of SARS-CoV-2 breakthrough infections among fully vaccinated (BBIBP-CorV) hospitalized patients have not yet been fully elucidated. Methods: In the single-center cohort study conducted at Xiangya Hospital of Central South University, we enrolled the hospitalized COVID-19 patients who had received full (2 doses) vaccination with the BBIBP-CorV vaccine between December 5, 2022, and January 31, 2023. We collected and analyzed information related to clinical characteristics, laboratory results, treatments, outcomes and prognostic data. Univariate and multivariable Cox regression were performed to assess the impact of clinical characteristics and laboratory results on the composite outcome (including the initiation of endotracheal intubation, non-invasive respiratory support, intensive care unit admission, and all-cause death). Results: A total of 572 COVID-19 hospitalized patients with fully vaccinated (BBIBP-CorV) were included. The median age of the patients was 66 years (IQR 53, 74). The most common symptoms included fever (347 [60.7 %]), dry cough (401 [70.1 %]), and expectoration (333 [58.2 %]). Among those with pre-existing chronic comorbidities, 44.2 % had hypertension and 20.5 % had diabetes. Laboratory tests revealed that the majority of patients (425/549 [77.4 %]) had normal white blood cell counts. Composite outcome occurred in 11.9 % of patients, with 96.7 % of patients discharged and 3.3 % of patients died. Multivariate Cox regression analyses suggested that the NLR >4 (adjusted HR,]; P = 0.008), D-dimer >0.5 mg/ml (adjusted
Ethics statement Our research has been approved by the institutional review committee of Xiangya Hospital of Central South University (202002024). All patients in the retrospective cohort study were anonymous, and the individual informed consent was not required. Y. Liu et al. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References
Albreiki, Mousa, Azman, Vurivi, Alhalwachi et al., Risk of hospitalization and vaccine effectiveness among COVID-19 patients in the UAE during the Delta and Omicron outbreaks, Front. Immunol
Andrews, Stowe, Kirsebom, Toffa, Rickeard et al., Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant, N. Engl. J. Med
Belayachi, Obtel, Mhayi, Razine, Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco, PLoS One
Creech, Walker, Samuels, Al Kaabi, Zhang et al., SARS-CoV-2 vaccines effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial, JAMA
Dawood, Increasing the frequency of omicron variant mutations boosts the immune response and may reduce the virus virulence, Microb. Pathog
Deng, Yin, Chen, Zeng, Clinical determinants for fatality of 44,672 patients with COVID-19, Crit. Care
Fiolet, Kherabi, Macdonald, Ghosn, Peiffer-Smadja, Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review, Clin. Microbiol. Infect
Grasselli, Zangrillo, Zanella, Antonelli, Cabrini et al., Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the lombardy region, Italy, JAMA
Hacisuleyman, Hale, Saito, Blachere, Bergh et al., Vaccine breakthrough infections with SARS-CoV-2 variants, N. Engl. J. Med
Heidarzadeh, Amini Moridani, Khoshmanesh, Kazemi, Hajiaghabozorgi et al., Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study, Int. J. Infect. Dis
Hu, Guo, Zhou, Shi, Characteristics of SARS-CoV-2 and COVID-19, Nat. Rev. Microbiol
Kuhlmann, Mayer, Claassen, Maponga, Burgers et al., Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose, Lancet
Laine, Cotton, Moyer, COVID-19 vaccine: what physicians need to know, Ann. Intern. Med
Li, Deng, Ye, Sun, Du et al., Clinical significance of plasma D-dimer in COVID-19 mortality, Front. Med
Li, Lin, Wu, Factors predicting re-hospitalization for inpatients with bipolar mania-A naturalistic cohort, Psychiatr. Res
Li, Wang, Tian, Pang, Yang et al., COVID-19 vaccine development: milestones, lessons and prospects, Signal Transduct. Targeted Ther
Li, Xu, Yu, Wang, Tao et al., Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan, J. Allergy Clin. Immunol
Lipsitch, Krammer, Regev-Yochay, Lustig, Balicer, SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact, Nat. Rev. Immunol
Liu, None
Metzler, Dvorsky, Wyss, Nordt, Walitza et al., Neurocognition in help-seeking individuals at risk for psychosis: prediction of outcome after 24 months, Psychiatr. Res
Peeling, Heymann, Teo, Garcia, Diagnostics for COVID-19: moving from pandemic response to control, Lancet
Ramasamy, Minassian, Ewer, Flaxman, Folegatti et al., Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial, Lancet
Sun, Jin, Dian, Shen, Zeng et al., Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study, EClinicalMedicine
Tan, Kwan, Rodriguez-Barraquer, Singer, Park et al., Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave, Nat. Med
Tian, Song, Zhang, Pan, Ge et al., Genomic, immunological, and clinical analysis of COVID-19 vaccine breakthrough infections in Beijing, China, J. Med. Virol
Wang, Guo, Iketani, Nair, Li et al., Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12, BA.4 and BA
Wang, Guo, Zeng, Sun, Lu et al., Transmission characteristics and inactivated vaccine effectiveness against transmission of SARS-CoV-2 omicron BA.5 variants in urumqi, China, JAMA Netw. Open
Wu, Chen, Cai, Xia, Zhou et al., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China, JAMA Intern. Med
Wu, Li, Liu, Wang, Zhou et al., Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b trial, Lancet Infect. Dis
Xia, Zhang, Wang, Wang, Yang et al., Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial, Lancet Infect. Dis
Xie, Ding, Li, Wang, Guo et al., Characteristics of patients with coronavirus disease (COVID-19) confirmed using an IgM-IgG antibody test, J. Med. Virol
Zeng, Li, Zeng, Deng, Huang et al., Can we predict the severity of coronavirus disease 2019 with a routine blood test?, Pol. Arch. Intern. Med
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit